Nautilus Biotechnolgy
NAUT
73 hedge funds and large institutions have $123M invested in Nautilus Biotechnolgy in 2023 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 25 increasing their positions, 16 reducing their positions, and 13 closing their positions.
56% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 16
49% more capital invested
Capital invested by funds: $82.9M → $123M (+$40.4M)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
1.29% less ownership
Funds ownership: 36.93% → 35.65% (-1.3%)
10% less funds holding
Funds holding: 81 → 73 (-8)
54% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 13
100% less call options, than puts
Call options by funds: $1K | Put options by funds: $1.83M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.39M |
| 2 |
Group One Trading
Chicago,
Illinois
|
+$313K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$154K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
+$124K |
| 5 |
Vanguard Capital Wealth Advisors
Denver,
Colorado
|
+$110K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$1.35M |
| 2 |
RI
RTW Investments
New York
|
-$1.08M |
| 3 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$809K |
| 4 |
DCMIC
Decheng Capital Management III (Cayman)
Grand Cayman,
Cayman Islands
|
-$540K |
| 5 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$522K |
NAUT Hedge Fund Activity: Q1 2023 in Review
73 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Nautilus Biotechnolgy (NAUT) for Q1 2023, worth a combined $123M — up 49% from $82.9M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of NAUT and 6 opened new positions — a net loss of 7 holders — while 16 trimmed existing stakes and 25 added.
The largest buyer was Vanguard Group, adding an estimated $1.39M. The largest seller was Rubric Capital Management (New York), exiting entirely with an estimated $1.35M sold.
- 73 institutional investors held Nautilus Biotechnolgy (NAUT) as of Q1 2023, down from 81 in Q4 2022.
- Funds reported $123M of Nautilus Biotechnolgy stock for Q1 2023, up 49% quarter-over-quarter.
- 6 funds opened new Nautilus Biotechnolgy positions in Q1 2023 and 13 closed out, a net change of -7 holders.
- The largest Nautilus Biotechnolgy buyer in Q1 2023 was Vanguard Group, an estimated $1.39M added.
- The largest Nautilus Biotechnolgy seller in Q1 2023 was Rubric Capital Management (New York), an estimated $1.35M sold.
Based on aggregated 13F filings for Q1 2023.